Education
About Us
Working with TipRanks
Follow Us
Ribomic, Inc. (JP:4591)
:4591
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥72.00 - ¥141.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥4.67B
Enterprise Value¥2.34B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding54,332,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.30
Price to Sales (P/S)1880.02
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA consistently debt-free balance sheet reduces refinancing risk and interest burdens, giving management more strategic optionality. Over 2-6 months this durable structural advantage lowers bankruptcy risk and eases capital-allocation choices versus highly leveraged peers, supporting runway management.
Positive Gross Profit When Revenue ExistsWhen sales occur, gross margins have been positive, suggesting underlying unit economics can be viable. This persistent gross-profit signal provides a foundation for scalable profitability if revenue growth resumes and operating expenses are controlled, a lasting structural prerequisite for biotech commercialization.
Cash Flow Aligns With Accounting LossesFree cash flow tracking net losses implies limited hidden non-cash drains and clearer cash dynamics. That transparency improves forecasting of runway and financing needs, a durable operational strength that aids planning and investor assessment over the medium term despite ongoing burn.
Bears Say
Sustained High Cash BurnPersistent annual operating cash outflows near ¥1.0B create a structural financing requirement. Over months this ongoing burn erodes flexibility, forces recurrent capital raises or cost cuts, and increases dilution or refinancing risk if revenue inflection does not materialize, pressuring long-term viability.
Minimal, Volatile Revenue BaseRevenue that is negligible and inconsistent prevents the company from leveraging fixed costs or building scale. Structurally, this undermines path to sustainable margins and heightens dependence on external funding; without durable commercial traction, profitability remains unlikely in the medium term.
Deep And Widening Operating LossesLarge, recurring net losses have materially eroded equity over time, halving reported shareholders' capital. This structural capital depletion limits investment capacity, raises dilution risk from future financings, and constrains the firm’s ability to fund R&D or commercialization without significant external capital.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥72.00 and its highest was ¥141.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.67B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is May 19, 2026 which is in 77 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on Feb 12, 2026. The company reported -¥4.67 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.67.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 54,332,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥4.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Linical Co., Ltd.
―
CanBas Co., Ltd.
―
Takara Bio Inc.
―